Start your day with a light meal, unless your doctor has said otherwise. Be sure to dress comfortably and wear something that ...

A once-weekly 7.2 mg dose of the drug, known as semaglutide but marketed as Wegovy for weight-loss, has shown to help patients lose an average of 20.7% of their body weight in late-stage trials ...

Novo Nordisk is also currently awaiting a decision from the FDA, having previously applied for approval of its Wegovy weight-loss pill. As part of the U.S. pricing deal with the administration earlier ...

The Food and Drug Administration is set to treat the application under its priority program to accelerate the review of ...

Minimally invasive dentistry is more than new tech; it’s a shift from 'drill and fill' to a philosophy of prevention and early intervention.

Nerandomilast, a PDE4B inhibitor, is a new treatment option for IPF, showing better tolerability than nintedanib and ...

Novo Nordisk files for FDA review of its higher-dose Wegovy after 72-week data show stronger weight loss than the current 2.4 ...

And one of them is pharmaceutical giant Pfizer ( PFE +1.98%). Now, with a major step along the path to entering this ...

Novo Nordisk is using its ticket for an extra-speedy regulatory review granted through the FDA’s Commissioner’s National ...

Through the FDA’s priority voucher program, Novo Nordisk said Nov. 26 it has filed an application seeking approval of its Wegovy 7.2 milligram injection.  Wegovy (semaglutide) is currently approved in ...